Chemomab Therapeutics's market cap is currently ―. The company's EPS TTM is $-2.105; its P/E ratio is -0.31; Chemomab Therapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-0.01. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Mar 23	Dec 22	Sep 22	Jun 22
Income Statement	-
Total Revenue	-	-	-	$ 0.00	$ 0.00
Gross Profit	-	-	$ 5.22M	-	-
EBIT	-	$ -8.73M	$ -8.05M	$ -8.32M	$ -6.25M
EBITDA	-	$ -8.72M	$ -8.03M	$ -8.30M	$ -6.24M
Net Income Common Stockholders	-	$ -9.07M	$ -8.75M	$ -8.08M	$ -6.19M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 19.78M	$ 20.77M	$ 39.97M	$ 46.47M	$ 51.72M
Total Assets	$ 22.15M	$ 35.01M	$ 43.06M	$ 50.22M	$ 56.38M
Total Debt	$ 392.00K	$ 177.00K	$ 214.00K	$ 244.00K	$ 280.00K
Net Debt	$ -19.39M	$ -20.59M	$ -39.76M	$ -46.22M	$ -51.44M
Total Liabilities	$ 5.15M	$ 7.06M	$ 6.84M	$ 5.59M	$ 4.54M
Stockholders Equity	$ 17.00M	$ 27.95M	$ 36.22M	$ 44.62M	$ 51.84M
Cash Flow	-
Free Cash Flow	-	$ -7.19M	$ -5.70M	$ -5.30M	$ -5.71M
Operating Cash Flow	-	$ -7.19M	$ -5.70M	$ -5.25M	$ -5.70M
Investing Cash Flow	-	$ 14.43M	$ 9.35M	$ 6.07M	$ 1.73M
Financing Cash Flow	-	-	$ -869.00K	$ 39.00K	$ 22.00K

Currency in USD

Chemomab Therapeutics Earnings and Revenue History

Income Statement >

Chemomab Therapeutics Debt to Assets

Balance Sheet >

Chemomab Therapeutics Cash Flow

Cash Flow >

Chemomab Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing